## Francesca Bonifazi

## List of Publications by Citations

**Source:** https://exaly.com/author-pdf/7920657/francesca-bonifazi-publications-by-citations.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

62 4,554 197 34 h-index g-index citations papers 5,487 4.71 209 5.4 avg, IF L-index ext. citations ext. papers

#	Paper	IF	Citations
197	Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 43-53	59.2	321
196	Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. <i>Blood</i> , <b>2001</b> , 98, 3074-81	2.2	275
195	A T-cell epitope encoded by a subset of HLA-DPB1 alleles determines nonpermissive mismatches for hematologic stem cell transplantation. <i>Blood</i> , <b>2004</b> , 103, 1417-24	2.2	151
194	A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia. <i>Blood</i> , <b>2002</b> , 99, 1527-35	2.2	147
193	Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3627-3637	2.2	147
192	Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome. <i>Haematologica</i> , <b>2009</b> , 94, 230-8	6.6	133
191	Treatment of refractory chronic GVHD with rituximab: a GITMO study. <i>Bone Marrow Transplantation</i> , <b>2007</b> , 40, 273-7	4.4	133
190	Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. <i>Leukemia</i> , <b>2007</b> , 21, 2316-23	10.7	124
189	Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. <i>Haematologica</i> , <b>2002</b> , 87, 1258	-64 <sup>6</sup>	124
188	Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state. <i>Blood</i> , <b>2002</b> , 99, 443-9	2.2	121
187	Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. <i>Lancet Haematology,the</i> , <b>2020</b> , 7, e157-e167	14.6	116
186	Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. <i>Leukemia</i> , <b>2012</b> , 26, 520-6	10.7	101
185	Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation. <i>Blood</i> , <b>2003</b> , 102, 1588-94	2.2	100
184	Infliximab treatment for steroid-refractory acute graft-versus-host disease. <i>Haematologica</i> , <b>2004</b> , 89, 1352-9	6.6	100
183	Larger Size of Donor Alloreactive NK Cell Repertoire Correlates with Better Response to NK Cell Immunotherapy in Elderly Acute Myeloid Leukemia Patients. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 1914-21	1 <sup>12.9</sup>	88
182	Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia. <i>Blood</i> , <b>2004</b> , 104, 4245-51	2.2	85
181	Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation. <i>Blood</i> , <b>2019</b> , 134, 892-899	2.2	64

180	Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey. <i>Clinical Infectious Diseases</i> , <b>2017</b> , 65, 1884-1896	11.6	63
179	Hemopoiesis in healthy old people and centenarians: well-maintained responsiveness of CD34+ cells to hemopoietic growth factors and remodeling of cytokine network. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , <b>2000</b> , 55, B61-6; discussion B67-70	6.4	63
178	Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. <i>Haematologica</i> , <b>2005</b> , 90, 225-31	6.6	61
177	Molecular response to imatinib in late chronic-phase chronic myeloid leukemia. <i>Blood</i> , <b>2004</b> , 103, 2284-9	9 <u>0</u> .2	60
176	Extranodal marginal zone B-cell lymphoma of MALT-type of the lung: single-center experience with 12 patients. <i>Leukemia and Lymphoma</i> , <b>2003</b> , 44, 821-4	1.9	57
175	Unrelated cord blood transplantation: outcomes after single-unit intrabone injection compared with double-unit intravenous injection in patients with hematological malignancies. <i>Transplantation</i> , <b>2013</b> , 95, 1284-91	1.8	52
174	Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party. <i>Leukemia</i> , <b>2016</b> , 30, 2047-2054	10.7	48
173	Stem cell mobilization and collection in patients with liver cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2008</b> , 27, 932-9	6.1	46
172	Cryotherapy in the prevention of oral mucositis in patients receiving low-dose methotrexate following myeloablative allogeneic stem cell transplantation: a prospective randomized study of the Gruppo Italiano Trapianto di Midollo Osseo nurses group. <i>Bone Marrow Transplantation</i> , <b>2007</b> ,	4.4	44
171	39, 347-52 Pleuroparenchymal fibroelastosis: the prevalence of secondary forms in hematopoietic stem cell and lung transplantation recipients. <i>Diagnostic and Interventional Radiology</i> , <b>2016</b> , 22, 400-6	3.2	42
170	Haploidentical Stem Cell Transplantation With Posttransplant Cyclophosphamide Therapy vs Other Donor Transplantations in Adults With Hematologic Cancers: A Systematic Review and Meta-analysis. <i>JAMA Oncology</i> , <b>2019</b> , 5, 1739-1748	13.4	41
169	HLA matching affects clinical outcome of adult patients undergoing haematopoietic SCT from unrelated donors: a study from the Gruppo Italiano Trapianto di Midollo Osseo and Italian Bone Marrow Donor Registry. <i>Bone Marrow Transplantation</i> , <b>2009</b> , 44, 571-7	4.4	39
168	Acute graft-versus-host disease and steroid treatment impair CD11c+ and CD123+ dendritic cell reconstitution after allogeneic peripheral blood stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2004</b> , 10, 106-15	4.7	39
167	Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT. <i>Bone Marrow Transplantation</i> , <b>2016</b> , 51, 351-7	4.4	37
166	Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation. <i>Haematologica</i> , <b>2006</b> , 91, 837-9	6.6	35
165	Liver Stiffness Measurement Allows Early Diagnosis of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome in Adult Patients Who Undergo Hematopoietic Stem Cell Transplantation: Results from a Monocentric Prospective Study. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> ,	4.7	34
164	Successful treatment of disseminated Fusariosis after allogeneic hematopoietic stem cell transplantation with the combination of voriconazole and liposomal amphotericin B. <i>Journal of Infection</i> , <b>2006</b> , 53, e243-6	18.9	34
163	Unrelated cord blood transplantation for adult patients with acute myeloid leukemia: higher incidence of acute graft-versus-host disease and lower survival in male patients transplanted with female unrelated cord blooda report from Eurocord, the Acute Leukemia Working Party, and the	22.4	33

Group for Blood and Marrow Transplantation. Journal of Hematology and Oncology, 2015, 8, 107

162	Short- and long-term haematological surveillance of healthy donors of allogeneic peripheral haematopoietic progenitors mobilized with G-CSF: a single institution prospective study. <i>Bone Marrow Transplantation</i> , <b>2005</b> , 36, 289-94	4.4	33
161	Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients. <i>Haematologica</i> , <b>2002</b> , 87, 816-21	6.6	32
160	Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised	14.6	31
159	Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. <i>Annals of Oncology</i> , <b>2016</b> , 27, 2251-2257	10.3	31
158	The CIBMTR score predicts survival of AML patients undergoing allogeneic transplantation with active disease after a myeloablative or reduced intensity conditioning: a retrospective analysis of the Gruppo Italiano Trapianto Di Midollo Osseo. <i>Leukemia</i> , <b>2013</b> , 27, 2086-91	10.7	31
157	Successful treatment of severe hemorrhagic cystitis with selective vesical artery embolization. Bone Marrow Transplantation, <b>2005</b> , 35, 529-30	4.4	31
156	Rabbit ATG/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel. <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 1093-1102	4.4	30
155	Diagnosis and Treatment of VOD/SOS After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 489	8.4	30
154	Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with alpha-interferon. Italian Cooperative Study Group on Chronic Myeloid Leukaemia. <i>British Journal of Haematology</i> , <b>2000</b> , 111, 587-95	4.5	29
153	Effect on survival of the development of late-onset non-infectious pulmonary complications after stem cell transplantation. <i>Haematologica</i> , <b>2006</b> , 91, 1268-72	6.6	29
152	Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System. <i>Leukemia</i> , <b>2017</b> , 31, 2449-2457	10.7	26
151	Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 1223-1233	2.2	25
150	Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation. <i>Haematologica</i> , <b>2000</b> , 85, 930-4	6.6	25
149	Detection of a novel specificity (CTLA-4) in ATG/TMG globulins and sera from ATG-treated leukemic patients. <i>Transplantation</i> , <b>2002</b> , 73, 1295-302	1.8	24
148	Validation of the acute leukemia-EBMT score for prediction of mortality following allogeneic stem cell transplantation in a multi-center GITMO cohort. <i>American Journal of Hematology</i> , <b>2017</b> , 92, 429-434	7.1	23
147	Meibomian Gland Dropout in Hematological Patients Before Hematopoietic Stem Cell Transplantation. <i>Cornea</i> , <b>2018</b> , 37, 1264-1269	3.1	23
146	Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and	4.4	22
145	EBMT (JACIE). Bone Marrow Transplantation, 2020, 55, 681-694  Dry Eye Disease Is Already Present in Hematological Patients Before Hematopoietic Stem Cell  Transplantation. Cornea, 2016, 35, 638-43	3.1	22

## (2003-2013)

144	Molecular monitoring of BCR-ABL transcripts after allogeneic stem cell transplantation for chronic myeloid leukemia. <i>Biology of Blood and Marrow Transplantation</i> , <b>2013</b> , 19, 735-40	4.7	21	
143	Glutathione transferase-A2 S112T polymorphism predicts survival, transplant-related mortality, busulfan and bilirubin blood levels after allogeneic stem cell transplantation. <i>Haematologica</i> , <b>2014</b> , 99, 172-9	6.6	21	
142	Cytomegalovirus and Epstein-Barr Virus DNA Kinetics in Whole Blood and Plasma of Allogeneic Hematopoietic Stem Cell Transplantation Recipients. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 1699-1706	4.7	20	
141	Role of imaging techniques in liver veno-occlusive disease diagnosis: recent advances and literature review. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2019</b> , 13, 463-484	4.2	19	
140	Intensification of GVHD prophylaxis with low-dose ATG-F before allogeneic PBSC transplantation from HLA-identical siblings in adult patients with hematological malignancies: results from a retrospective analysis. <i>Bone Marrow Transplantation</i> , <b>2012</b> , 47, 1105-11	4.4	19	
139	Use of anti-BDCA-2 antibody for detection of dendritic cells type-2 (DC2) in allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , <b>2002</b> , 29, 887-91	4.4	19	
138	Ocular surface analysis in hematological patients before and after allogeneic hematopoietic stem cell transplantation: implication for daily clinical practice. <i>Eye</i> , <b>2017</b> , 31, 1417-1426	4.4	18	
137	Use of eltrombopag in aplastic anemia in Europe. <i>Annals of Hematology</i> , <b>2019</b> , 98, 1341-1350	3	18	
136	Assessment and prevention of cytomegalovirus infection in allogeneic hematopoietic stem cell transplant and in solid organ transplant: A multidisciplinary consensus conference by the Italian GITMO, SITO, and AMCLI societies. <i>Clinical Transplantation</i> , <b>2019</b> , 33, e13666	3.8	18	
135	Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia. <i>American Journal of Hematology</i> , <b>2018</b> , 93, 1211-1219	7.1	17	
134	Allogeneic stem cell transplantation in therapy-related acute myeloid leukemia and myelodysplastic syndromes: impact of patient characteristics and timing of transplant. <i>Leukemia and Lymphoma</i> , <b>2012</b> , 53, 96-102	1.9	17	
133	Allogeneic hematopoietic cell transplantation from unrelated donors in multiple myeloma: study from the Italian Bone Marrow Donor Registry. <i>Biology of Blood and Marrow Transplantation</i> , <b>2013</b> , 19, 940-8	4.7	17	
132	Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: a retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO). <i>Bone Marrow Transplantation</i> , <b>2017</b> , 52, 955-961	4.4	16	
131	Slug/Etatenin-dependent proinflammatory phenotype in hypoxic breast cancer stem cells. <i>American Journal of Pathology</i> , <b>2013</b> , 183, 1688-1697	5.8	16	
130	Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia. Haematologica, <b>2003</b> , 88, 256-9	6.6	16	
129	Autologous stem cell transplantation is still a valid option in good- and intermediate-risk AML: a GITMO survey on 809 patients autografted in first complete remission. <i>Bone Marrow Transplantation</i> , <b>2017</b> , 52, 163-166	4.4	15	
128	Busulfan neurotoxicity and EEG abnormalities: a case report. Neurological Sciences, 2004, 25, 95-7	3.5	15	
127	Allogeneic graft CD34(+) cell dose correlates with dendritic cell dose and clinical outcome, but not with dendritic cell reconstitution after transplant. <i>Experimental Hematology</i> , <b>2003</b> , 31, 959-65	3.1	15	

126	Reduced incidence of GVHD without increase in relapse with low-dose rabbit ATG in the preparative regimen for unrelated bone marrow transplants in CML. <i>Bone Marrow Transplantation</i> , <b>2003</b> , 32, 237-42	4.4	15
125	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors: A Registry-Based Study of the Italian Blood and Marrow Transplantation Society	4.7	14
124	Antilymphocyte Globulin for Chronic Graft-versus-Host Disease. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 1894-5	59.2	14
123	Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 932-940	4.7	14
122	Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy. <i>Blood</i> , <b>2000</b> , 95, 2234-9	2.2	14
121	Steroid treatment of acute grafthost disease grade I: a randomized trial. <i>Haematologica</i> , <b>2017</b> , 102, 2125-2133	6.6	13
120	Saprochaete clavata infections in patients undergoing treatment for haematological malignancies: A report of a monocentric outbreak and review of the literature. <i>Mycoses</i> , <b>2019</b> , 62, 1100-1107	5.2	13
119	Hairy cell leukemia: allogeneic transplantation could be an optimal option in selected patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2012</b> , 12, 287-9	2	13
118	Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients. <i>Leukemia</i> , <b>2012</b> , 26, 1779-85	10.7	13
117	Ribosomal DNA instability: An evolutionary conserved fuel for inflammaging. <i>Ageing Research Reviews</i> , <b>2020</b> , 58, 101018	12	13
116	Imaging in Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 1770-1779	4.7	12
115	Successful treatment of multi-resistant Pseudomonas aeruginosa osteomyelitis after allogeneic bone marrow transplantation with a combination of colistin and tigecycline. <i>Journal of Medical Microbiology</i> , <b>2007</b> , 56, 1692-1695	3.2	12
114	In vivo T-cell depletion with low-dose ATG is effective in reducing cGVHD after peripheral blood stem cell myeloablative sibling transplants in CML: results from a prospective phase II study. <i>Bone Marrow Transplantation</i> , <b>2005</b> , 35, 1025-6	4.4	12
113	Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-alpha-based therapy. <i>Bone Marrow Transplantation</i> , <b>2000</b> , 25, 729-36	4.4	12
112	Eyelid metrics assessment in patients with chronic ocular graft versus-host disease. <i>Ocular Surface</i> , <b>2019</b> , 17, 98-103	6.5	12
111	392: Delayed Recovery of Myeloid (mDC) and Plasmacytoid (pDC) Dendritic Cells at 3 Months after Allogeneic HSC Transplantation Correlates with an Increased Transplant-related and Overall Mortality Independently of GVHD. <i>Biology of Blood and Marrow Transplantation</i> , <b>2008</b> , 14, 142-143	4.7	11
110	Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party. <i>Cancer</i> , <b>2019</b> , 125, 90-98	6.4	11
109	Higher numbers of blood CD14+ cells before starting conditioning regimen correlate with greater risk of acute graft-versus-host disease in allogeneic stem cell transplantation from related donors.  Biology of Blood and Marrow Transplantation, 2007, 13, 228-34	4.7	10

## (2000-2019)

108	Intrabone transplant provides full stemness of cord blood stem cells with fast hematopoietic recovery and low GVHD rate: results from a prospective study. <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 717-725	4.4	10
107	The Rome Transplant Network model compared to the Italian Bone Marrow Donor Registry activity for unrelated donor search process and transplant efficiency for hematologic malignancy. <i>Transfusion</i> , <b>2017</b> , 57, 1734-1743	2.9	9
106	Treatment of steroid resistant acute graft versus host disease with an anti-CD26 monoclonal antibody-Begelomab. <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 1580-1587	4.4	9
105	Thiotepa-based conditioning for allogeneic stem cell transplantation in acute lymphoblastic leukemia-A survey from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>American Journal of Hematology</i> , <b>2017</b> , 92, 18-22	7.1	9
104	Prevention of Chronic GvHD after HLA-Identical Sibling Peripheral Hematopietic Stem Cell Transplantation with or without Anti-Lymphocyte Globulin (ATG). Results from a Prospective, Multicenter Randomized Phase III Trial (ATGfamilystudy). <i>Blood</i> , <b>2014</b> , 124, 37-37	2.2	9
103	The role of extracellular DNA in COVID-19: Clues from inflamm-aging. <i>Ageing Research Reviews</i> , <b>2021</b> , 66, 101234	12	9
102	Positive HCMV DNAemia in stem cell recipients undergoing letermovir prophylaxis is expression of abortive infection. <i>American Journal of Transplantation</i> , <b>2021</b> , 21, 1622-1628	8.7	9
101	A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensity-score weighted multicenter approach. <i>American Journal of Hematology</i> , <b>2017</b> , 92, E557-E559	7.1	8
100	Clinical utility of measuring Epstein-Barr virus-specific cell-mediated immunity after HSCT in addition to virological monitoring: results from a prospective study. <i>Medical Microbiology and Immunology</i> , <b>2019</b> , 208, 825-834	4	8
99	Molecular monitoring of acute myeloid leukemia associated with inv(16): threshold of CBFbeta/MYH11 transcript copy number above which relapse occurs and below which continuous Complete Remission is likely. <i>Leukemia</i> , <b>2003</b> , 17, 650-1; author reply 651-2	10.7	8
98	A phase II study of alpha-interferon and oral arabinosyl cytosine (YNK01) in chronic myeloid leukemia. <i>Leukemia</i> , <b>2003</b> , 17, 554-9	10.7	8
97	Incidence, Risk Factors and Complications of Ocular Graft-Versus-Host Disease Following Hematopoietic Stem Cell Transplantation. <i>American Journal of Ophthalmology</i> , <b>2021</b> , 227, 25-34	4.9	8
96	Clinical value of quantitative long-term assessment of bcr-abl chimeric transcript in chronic myelogenous leukemia patients after allogeneic bone marrow transplantation. <i>Haematologica</i> , <b>2000</b> , 85, 653-8	6.6	8
95	Umbilical cord blood versus unrelated donor transplantation in adults with primary refractory or relapsed acute myeloid leukemia: a report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the EBMT.	7	7
94	Longitudinal Analysis of Infrared Meibography in Patients Undergoing Hematopoietic Stem Cell Transplantation. <i>Cornea</i> , <b>2020</b> , 39, 812-817	3.1	7
93	Contemporaneous appearance, 18 years after allogeneic bone marrow transplantation, of myelodysplastic syndrome in the patient and the donor. <i>Bone Marrow Transplantation</i> , <b>2004</b> , 33, 859-61	4.4	7
92	Alemtuzumab in the treatment of relapsed acute lymphoid leukaemia. <i>Leukemia</i> , <b>2005</b> , 19, 135; author reply 136	10.7	7
91	Different immune reconstitution in multiple myeloma, chronic myeloid leukemia and acute myeloid leukemia patients after allogeneic transplantation of peripheral blood stem cells. <i>Bone Marrow Transplantation</i> , <b>2000</b> , 26, 1325-31	4.4	7

90	Comparative evaluation of biological human leukocyte antigen DPB1 mismatch models for survival and grafthost disease prediction after unrelated donor hematopoietic cell transplantation. Haematologica, <b>2020</b> , 105, e186-e189	6.6	7	
89	Radioimmunotherapy-augmented BEAM chemotherapy vs BEAM alone as the high-dose regimen for autologous stem cell transplantation (ASCT) in relapsed follicular lymphoma (FL): a retrospective study of the EBMT Lymphoma Working Party. <i>Bone Marrow Transplantation</i> , <b>2017</b> , 52, 1	4·4 120-112	6 2 <b>5</b>	
88	Successful management of EBV-PTLD in allogeneic bone marrow transplant recipient by virological-immunological monitoring of EBV infection, prompt diagnosis and early treatment. <i>Transplant Immunology</i> , <b>2016</b> , 34, 60-4	1.7	6	
87	Low-Dose Anti-T Lymphoglobulin as Prophylaxis for Graft-versus-Host Disease in Unrelated Donor Transplantations for Acute Leukemias and Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 2450-2458	4.7	6	
86	Effectiveness of fludarabine, idarubicin and cyclophosphamide (FLUIC) combination regimen for young patients with untreated non-follicular low-grade non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , <b>2004</b> , 45, 1815-9	1.9	6	
85	Double reinforcement with fludarabine/high-dose cytarabine enhances the impact of autologous stem cell transplantation in acute myeloid leukemia patients. <i>Bone Marrow Transplantation</i> , <b>2001</b> , 27, 829-35	4.4	6	
84	Comparison among different diagnostic criteria for chronic ocular graft-versus-host disease applied with and without pre-transplant ophthalmological examination. <i>Eye</i> , <b>2019</b> , 33, 154-160	4.4	6	
83	Outcomes of Advanced Hodgkin Lymphoma after Umbilical Cord Blood Transplantation: A Eurocord and EBMT Lymphoma and Cellular Therapy & Immunobiology Working Party Study. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 2265-2270	4.7	5	
82	Reduced-Intensity Conditioning (RIC) Followed by Allogeneic Transplantation in Relapsed Lymphomas: Evidence for Graft-Versus-Lymphoma Effect in Low and High Grade Histologies, but Not in Hodgkin Disease <i>Blood</i> , <b>2004</b> , 104, 808-808	2.2	5	
81	Autologous stem cell transplantation for acute myeloid leukemia patients in first complete remission: a 10-year follow-up study of 118 patients. <i>Haematologica</i> , <b>2005</b> , 90, 139-41	6.6	5	
80	OCCUPATION study (OCCUPationl asthma: a naTIONal based study): a survey on occupational asthma awareness among Italian allergists. <i>European Annals of Allergy and Clinical Immunology</i> , <b>2014</b> , 46, 26-9	1.3	5	
79	Antiemetic prophylaxis in patients undergoing hematopoietic stem cell transplantation: a multicenter survey of the Gruppo Italiano Trapianto Midollo Osseo (GITMO) transplant programs.  Annals of Hematology, 2020, 99, 867-875	3	4	
78	'Real-life' report on the management of chronic GvHD in the Gruppo Italiano Trapianto Midollo Osseo (GITMO). <i>Bone Marrow Transplantation</i> , <b>2018</b> , 53, 58-63	4.4	4	
77	Factors influencing the perception of protective isolation in patients undergoing haematopoietic stem cell transplantation: A multicentre prospective study. <i>European Journal of Cancer Care</i> , <b>2019</b> , 28, e13148	2.4	4	
76	Impact of Educational Interventions on Psychological Distress During Allogeneic Hematopoietic Stem Cell Transplantation: A Randomised Study. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , <b>2020</b> , 12, e2020067	3.2	4	
75	Haploidentical related donor compared to HLA-identical donor transplantation for chemosensitive Hodgkin lymphoma patients. <i>BMC Cancer</i> , <b>2020</b> , 20, 1140	4.8	4	
74	A case of pseudothrombocytosis. <i>Haematologica</i> , <b>1999</b> , 84, 275	6.6	4	
73	New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?. Expert	5.4	3	

Nilotinib in steroid-refractory cGVHD: prospective parallel evaluation of response, according to NIH 72 criteria and exploratory response criteria (GITMO criteria). Bone Marrow Transplantation, **2020**, 55, 2077- $\frac{1}{20}$ 86  $\frac{3}{20}$ Transplantation Induces Profound Changes in the Transcriptional Asset of Hematopoietic Stem Cells: Identification of Specific Signatures Using Machine Learning Techniques. Journal of Clinical 5.1 Medicine, 2020, 9, Effect of the Thiotepa Dose in the TBF Conditioning Regimen in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission: A Report From the 70 3 EBMT Acute Leukemia Working Party. Clinical Lymphoma, Myeloma and Leukemia, 2020, 296-304 Access to alternative donor hematopoietic search and transplantation for acute leukemia in 69 different macro-regions of Italy. A GITMO/IBMDR study. Bone Marrow Transplantation, 2018, 53, 291-299<sup>4.4</sup> 68 15 or 33 years of cord-blood transplantation?. Lancet, The, 2003, 361, 1566-7 40 3 Umbilical-cord blood for transplantation in adults. New England Journal of Medicine, 2005, 352, 67 59.2 935-7; author reply 935-7 Unrelated Cord Blood Transplantation: Comparison After Single Unit Cord Blood Intrabone 66 Injection and Double Unit Cord Blood Transplantation In Patients with Hematological Malignant 2.2 3 Disorders. A Eurocord-EBMT Analysis. Blood, 2010, 116, 223-223 Longitudinal Corneal Endothelial Cell Changes in Patients Undergoing Hematopoietic Stem Cell 65 3.1 Transplantation. Cornea, 2021, 40, 462-466 The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after 64 3 autologous stem cell transplant in multiple myeloma. Bone Marrow Transplantation, 2020, 55, 946-954 Veno-occlusive disease nurse management: development of a dynamic monitoring tool by the 63 2.7 GITMO nursing group. *Ecancermedicalscience*, **2016**, 10, 661 Patterns of AML1-ETO transcript expression in patients with acute myeloid leukemia and t(8;21) in 62 6.6 3 complete hematologic remission. *Haematologica*, **2004**, 89, 103-5 Hematopoietic mixed chimerism after allogenic BMT. Transfusion, 2003, 43, 1758-9 61 2.9 Quantitative Assessment of Indoleamine 2,3-Dioxygenase (IDO) Expression at Diagnosis Predicts 60 Clinical Outcome in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell 2 2.2 Transplantation. Blood, 2018, 132, 5261-5261 Reduced-Intensity Conditioning Followed by Allogeneic Stem Cell Transplantation (allo-SCT) Is an Effective Salvage Treatment for Peripheral T-Cell Non-Hodgkin Lymphoma (PTCL).. Blood, 2005, 2.2 2 59 106, 1128-1128 Engraftment, clinical, and molecular follow-up of patients with multiple myeloma who were reinfused with highly purified CD34+ cells to support single or tandem high-dose chemotherapy. 58 2.2 2 Blood, 2000, 95, 2234-2239 Single nucleotide polymorphisms of the factor IX gene for linkage analysis in the southern Chinese 57 4.5 population. British Journal of Haematology, 2000, 111, 540-3 Veno-occlusive Disease in HSCT Patients: Consensus-based Recommendations for Risk Assessment, 1.8 56 2 Diagnosis, and Management by the GITMO Group. Transplantation, 2021, 105, 686-694 Donor Lymphocyte Infusions After Allogeneic Stem Cell Transplantation in Acute Leukemia: A 55 Survey From the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Frontiers in Oncology, 2020, 10, 5729 8

54	Development and initial validation of a questionnaire to assess patients' perception of protective isolation following haematopoietic stem cell transplantation. <i>European Journal of Cancer Care</i> , <b>2019</b> , 28, e12955	2.4	2
53	Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia <i>Cancer Medicine</i> , <b>2021</b> ,	4.8	2
52	MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia. <i>European Journal of Haematology</i> , <b>2020</b> , 105, 47-55	3.8	1
51	Disposal of the residual autologous HSC units: Results of a survey carried out two years after the publication of a national policy in Italy. <i>Transfusion and Apheresis Science</i> , <b>2018</b> , 57, 197-200	2.4	1
50	Pretransplant Recipient Blood CD14+ preDC Levels Correlate with Increased Acute GVHD after Allogeneic PBSC Transplantation <i>Blood</i> , <b>2004</b> , 104, 1226-1226	2.2	1
49	PEG Intron Treatment in 90 Patients with Essential Thrombocythemia (ET) Final Report of a Phase II Study <i>Blood</i> , <b>2005</b> , 106, 2600-2600	2.2	1
48	Long-Term Follow-up of Patients Affected by Relapsed Lymphomas Receiving Reduced-Intensity Conditioning (RIC) Regimen Followed by Allogeneic Stem Cell Transplantation (Allo-SCT): An Update of the Phase II Study of the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO). <i>Blood</i> ,	2.2	1
47	<b>2008</b> , 112, 3303-3303 Allogeneic Bone Marrow Transplantation From Unrelated Donors in Multiple Myeloma: A Study from the Italian Bone Marrow Transplantation Donor Registry. <i>Blood</i> , <b>2011</b> , 118, 2009-2009	2.2	1
46	Bronchiolitis Obliterans Syndrome after Hematopoietic Stem Cell Transplantation: A Retrospective Multicenter Survey of the Late Effect Working Party EBMT <i>Blood</i> , <b>2006</b> , 108, 3363-3363	2.2	1
45	Allelic HLA Matching and Pair Origin Are Favorable Prognostic Factors for Unrelated Hematopoietic Stem Cell Transplantation in Neoplastic Hematologic Diseases: An Italian Analysis by the Gruppo Italiano Trapianto di Cellule Staminali e Terapie Cellulari, Italian Bone Marrow Donor Registry, and		1
44	Management of Pain and Anxiety during Bone Marrow Aspiration: An Italian National Survey. <i>Pain Management Nursing</i> , <b>2021</b> , 22, 349-355	2.5	1
43	Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients. <i>Leukemia Research</i> , <b>2021</b> , 101, 106.	497	1
42	ALL-073: Inotuzumab Ozogamicin (IO) and Donor Lymphocyte Infusion (DLI) are a Safe and Promising Combination in Relapsed Acute Lymphoblastic Leukemia (ALL) After Allogeneic Hematopoietic Stem Cell Transplant (HSCT). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2020</b> , 20, S161	2	0
41	Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 804988	8.4	O
40	Bone Marrow Evaluation According to the PVSG and WHO Criteria in 90 Essential Thrombocythemia (ET) Patients Treated with PEG Interferon alpha-2b. Preliminary Results <i>Blood</i> , <b>2005</b> , 106, 4962-4962	2.2	О
39	GITMO REGISTRY STUDY ON ALLOGENEIC TRANSPLANTATION IN PATIENTS AGED OVER 60 FROM 2000 TO 2017. IMPROVEMENTS AND CRITICISMS. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> , 28, 96.e1-	96.e1	О
38	Decades of Progress in Allogeneic Stem Cell Transplantation for Multiple Myeloma. <i>Hemato</i> , <b>2021</b> , 2, 89-102	0.2	O
37	Longitudinal Tear Protein Changes Correlate with Ocular Chronic GVHD Development in Allogeneic Hematopoietic Stem Cell Transplant Patients. <i>Applied Sciences (Switzerland)</i> , <b>2021</b> , 11, 8221	2.6	O

36	Effect of prophylactic or pre-emptive use of tyrosine kinase inhibitors post-Allo SCT in bcr-abl positive acute lymphoblastic leukemia: a subanalysis of GITMO ph-positive ALL study <i>Bone Marrow Transplantation</i> , <b>2022</b> ,	4.4	0
35	Nursing role in the assessment and care of hepatic sinusoidal obstruction syndrome patients: a consensus paper by the "Gruppo Italiano Trapianto di Midollo Osseo". <i>Supportive Care in Cancer</i> , <b>2020</b> , 28, 5125-5137	3.9	
34	Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients. <i>Leukemia and Lymphoma</i> , <b>2013</b> , 54, 1791-3	1.9	
33	BRENTUXIMAB VEDOTIN FOR RELAPSED HODGKIN LYMPHOMA AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: a RETROSPECTIVE STUDY OF THE EBMT LYMPHOMA WORKING PARTY. <i>Hematological Oncology</i> , <b>2017</b> , 35, 83-84	1.3	
32	GVHD and prognostic factors. American Journal of Hematology, 2006, 81, 221-2	7.1	
31	Reply to Pfirrmann and Hasford. British Journal of Haematology, 2001, 114, 241-242	4.5	
30	Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with Enterferon. <i>British Journal of Haematology</i> , <b>2000</b> , 111, 587-595	4.5	
29	Allergy to latex. Lancet, The, <b>2000</b> , 355, 850	40	
28	Patient-Reported Outcomes (PROs) Among Patients With Steroid-Refractory or -Dependent Chronic Graft-vs-Host Disease (cGVHD) Randomized to Ruxolitinib (RUX) vs Best Available Therapy (BAT). <i>Blood</i> , <b>2021</b> , 138, 3909-3909	2.2	
27	Overall Survival Improvement Following ALLO-SCT in Patients Older THAN 60 YEARS: A Gruppo Italiano Trapianto DI Midollo Osseo (GITMO) Registry Study. <i>Blood</i> , <b>2021</b> , 138, 1786-1786	2.2	
26	Imatinib Therapy for Chronic Myeloid Leukemia Patients Who Relapse after Allogeneic Stem Cell Transplantation: A Molecular Analysis <i>Blood</i> , <b>2004</b> , 104, 4655-4655	2.2	
25	Phase II Study of a Single Pegfilgrastim Injection as Adjunct to Chemotherapy to Mobilize Stem Cells into Peripheral Blood of Resistant/Relapsed Lymphoma Patients <i>Blood</i> , <b>2004</b> , 104, 2871-2871	2.2	
24	A Pilot Study To Evaluate the Safety, Efficacy and Effects on Liver Function of Granulocyte Colony-Stimulating Factor To Mobilize Hematopoietic Stem Cells in Patients with Liver Cirrhosis <i>Blood</i> , <b>2005</b> , 106, 1698-1698	2.2	
23	High Resolution Donor/Recipient HLA Matching Level in Unrelated Hematopoietic Stem Cell Transplantation and Impact on the Transplant Outcome: The Italian Experience on Behalf of GITMO, IBMDR and Aibt. <i>Blood</i> , <b>2018</b> , 132, 4642-4642	2.2	
22	Permissive HLA-DPB1 Mismatch and Survival after Unrelated Donor Allogeneic Stem Cell Transplantation for Hematological Malignancies: A Comparative Analysis of Different Immunogenetic Models on 422 Patients from GITMO and IBMDR. <i>Blood</i> , <b>2018</b> , 132, 482-482	2.2	
21	Outcomes after Unrelated Cord Blood Transplantation (UCBT) in Patients with Chronic Myeloid Leukemia (CML): A Retrospective Study from the Cmwp-EBMT. <i>Blood</i> , <b>2018</b> , 132, 3475-3475	2.2	
20	Post-Transplant Cyclophosphamide Versus Antithymocyte Globulin in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation from One Antigen HLA-Mismatched Donors: A Retrospective Analysis from the Acute Leukemia Working Party of the EBMT. <i>Blood</i> , <b>2018</b> , 132, 1016-1016	2.2	
19	Eltrombopag for the Treatment of Aplastic Anemia in Europe. <i>Blood</i> , <b>2018</b> , 132, 1304-1304	2.2	

18	Transplant: Results from a Prospective Study. <i>Blood</i> , <b>2018</b> , 132, 2098-2098	2.2
17	Management ATG (SIRS) <b>2019</b> , 183-187	
16	Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Therapy-Related Myeloid Neoplasm: A Study from the Chronic Malignancies Working Party of the EBMT. <i>Blood</i> , <b>2019</b> , 134, 45-45	2.2
15	Vascular and Parenchymal Alterations of the Liver and Liver Surveillance in Patients Who Received Inotuzumab Ozogamicin As the Standard of Care for Relapse/Refractory Acute Lymphoblastic Leukemia. <i>Blood</i> , <b>2019</b> , 134, 1343-1343	2.2
14	Factors Predicting Outcome after Allogeneic Stem Cell Transplantation in Primary Refractory Acute Myeloid Leukemia: A Retrospective Analysis of the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO). <i>Blood</i> , <b>2014</b> , 124, 731-731	2.2
13	Donor Natural Killer (NK) Alloreactivity Predicts Long-Term Relapse-Free Survival in Acute Myeloid Leukemia Patients Undergoing Immunotherapy with NK Cells. <i>Blood</i> , <b>2014</b> , 124, 624-624	2.2
12	Long-Term Clinical Outcomes of Allogeneic Stem Cell Transplantation in Multiple Myeloma. <i>Blood</i> , <b>2015</b> , 126, 1968-1968	2.2
11	Thiotepa-Based Conditioning for Allogeneic Stem Cell Transplantation (allo-HSCT) in Acute Lymphoblastic Leukaemia (ALL) - a Survey from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , <b>2015</b> , 126, 4316-4316	2.2
10	Prediction of Allogeneic Stem Cell Transplantation Mortality in Patients with Acute Leukemia (AL) Using the AL- European Society for Blood and Marrow Transplantation (EBMT) Risk Score in the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO) Data Set: A Study on Behalf of the AL Working	2.2
9	Party (ALWP) of the EBMT and GITMO. <i>Blood</i> , <b>2016</b> , 128, 989-989  Driver Somatic Mutations and Transplantation Decision Making in Patients with Myelodysplastic Syndrome. <i>Blood</i> , <b>2016</b> , 128, 53-53	2.2
8	Allogeneic Stem Cell Transplantation (Allo-SCT) Following a Reduced-Intensity Conditioning (RIC) Regimen in Relapsed Peripheral T-Cell Lymphomas (PTCL): Results at 4 Year of Median Follow-up <i>Blood</i> , <b>2009</b> , 114, 875-875	2.2
7	Allogeneic Stem Cell Transplantation in Patients with Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndromes: Effect of Patient Characteristics and Treatment History <i>Blood</i> , <b>2010</b> , 116, 4577-4577	2.2
6	Long Term Study of the Impact of Quantitative Molecular Monitoring of Bcr-Abl Transcripts on the Risk of Relapse of CML After Allogeneic HSCT <i>Blood</i> , <b>2010</b> , 116, 1287-1287	2.2
5	Validation of the New European LeukemiaNet (ELN) Recommendations for Bcr-Abl Kinase Domain Mutation Analysis In Chronic Myeloid Leukemia: An Analysis of the GIMEMA CML Working Party Studies. <i>Blood</i> , <b>2011</b> , 118, 112-112	2.2
4	Validation of the Cibmtr Score in Predicting the Outcome of Hematopoietic Stem-Cell Transplantation in AML Patients Not in Complete Remission At the Time of Conditioning: A Retrospective Analysis On Behalf of the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO). Blood	2.2
3	, <b>2012</b> , 120, 2005-2005  Clinical Efficacy of Ponatinib in Philadelphia-Positive T-Cell Acute Lymphoblastic Leukemia with Extramedullary Involvement. <i>Acta Haematologica</i> , <b>2021</b> , 144, 688-692	2.7
2	Low doses ATLG as GvHD prophylaxis in allogeneic hematopoietic stem cell transplantation for lymphomas. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 2295-2298	4-4
1	Availability of HLA-allele-matched unrelated donors and registry size: Estimation from haplotype frequency in the Italian population. <i>Human Immunology</i> , <b>2021</b> , 82, 758-766	2.3